Furiex Pharmaceuticals, Inc. 4
4 · Furiex Pharmaceuticals, Inc. · Filed Jul 23, 2013
Insider Transaction Report
Form 4
McIntyre Gail Frances
Senior Vice President-Research
Transactions
- Sale
Common Stock
2013-07-19$40.00/sh−10,581$423,240→ 17,868 total - Tax Payment
Common Stock
2013-07-19$40.00/sh−9,419$376,760→ 28,449 total - Exercise/Conversion
Stock Options (to buy)
2013-07-19+20,000→ 55,691 totalExercise: $9.11Exp: 2020-06-17→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2013-07-19$9.11/sh+20,000$182,200→ 37,868 total
Holdings
- 26,000
Stock Options (to buy)
Exercise: $15.00Exp: 2021-05-09→ Common Stock (26,000 underlying) - 37,944
Stock Options (to buy)
Exercise: $13.16Exp: 2021-10-03→ Common Stock (37,944 underlying) - 10,368
Stock Options (to buy)
Exercise: $17.80Exp: 2022-02-24→ Common Stock (10,368 underlying)
Footnotes (5)
- [F1]This sale was pursuant to a Rule 10b5-1 Sales Plan, which is intended to comply with Rule 10b5-1.
- [F2]The options were awarded on 6/17/2010 and vest over three years, with one-third vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.
- [F3]The options were awarded on 5/9/2011. One-third of the options vest on the date of grant and the remaining two-thirds vest in two equal annual installments on the first and second anniversaries of the date of grant, provided the Optionee's employment continues.
- [F4]The options were awarded on 10/3/2011 and vest over three years, with one-third vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.
- [F5]The options were awarded on 2/24/2012 and vest over three years, with one-third vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.